GHK-Cu: skin-care evidence, safety and FDA status

A cosmetic, a prescription cream and an injection are different exposures. GHK-Cu has small, heterogeneous human reports; ingredient familiarity cannot establish that any particular product works or is safe. The current FDA non-injectable Category 1 entry is conditional interim policy, not drug approval ^[3].

GHK-Cu is a small copper-binding peptide best known from skin care

GHK is a chain of just three amino acids: glycine, histidine and lysine. Bound to a copper ion, it becomes GHK-Cu. On a skin-care label you'll usually see it as copper tripeptide-1, its cosmetic ingredient name, or simply "copper peptide."

GHK-Cu is a copper complex, not growth hormone. Laboratory hypotheses and narrative reviews should be distinguished from clinical outcomes in people. The claim-by-claim evidence review makes that distinction for skin, hair, wounds and systemic marketing.

What GHK-Cu is claimed to do, and where those claims come from

A narrative review from researchers affiliated with Skin Biology summarizes laboratory wound and gene-expression findings ^[8]. Such a review can explain a claim’s origin, but is not an independent clinical trial or proof of slower human aging.

Lab and animal findings are a reason to run trials, not a substitute for them. A cream's effect on a person's face depends on whether the peptide gets through the skin, at what strength and for how long, and none of that is answered by a cell study.

Human studies cover distinct products and outcomes

In the laser-resurfacing randomized trial, patients used skin care with or without GHK-Cu after CO2 laser resurfacing around the mouth. Thirteen completed the study ^[6]. Computer analysis and blinded evaluators found no difference between groups in how fast redness faded, and no difference in wrinkles or overall skin quality at 12 weeks.

Patients using GHK-Cu rated skin quality more favorably (P=.04), although the objective measures did not differ ^[6]. That endpoint distinction matters: the small postoperative study cannot establish a reliable benefit for everyday aging skin. See the topical evidence review.

Injected findings do not establish isolated systemic benefit

The reviewed evidence does not establish controlled systemic benefit from isolated injected GHK-Cu. The closest is a 2018 open-label study from a cosmetic clinic in India that injected a hair formulation into the scalps of 1,000 people ^[7]. That formulation held six ingredients: four growth factors, thymosin beta-4 and copper tripeptide-1. The authors reported less hair shedding in 83% of patients, but with no control group and six actives in one shot, the study can't say what GHK-Cu did, if anything. FDA's safety-risks page says compounded injectable GHK-Cu may pose a risk of immune reactions because of aggregation and peptide-related impurities, and that human data to inform safety are limited ^[4].

Injection skips the skin barrier that limits what a cream can deliver. That is the appeal for buyers, and it is also why FDA treats the two routes separately: a contaminant or a clumped peptide sitting on the skin is a very different risk from the same thing injected into tissue. The open safety questions for both routes are in is GHK-Cu safe.

The current FDA entry excludes injectable use. Withdrawal of a nomination is not an approval or a safety finding ^[4]. Routine commercial bulk compounding and authorized clinical investigation have separate requirements; a seller’s research label supplies neither approval nor authorization.

Two legal tracks: a cosmetic ingredient or a compounded drug

Whether a GHK-Cu product is a cosmetic or a drug depends on what it claims to do, not on what is in it. FDA says cosmetics generally do not need premarket approval, except certain color additives ^[5]. Claims that a product will affect the body's structure or function, such as regenerating cells or restoring hair growth, make it a drug, even if it is sold as a cosmetic.

FDA also notes that "cosmeceutical" has no meaning under the law ^[5]. A copper-peptide serum sold to improve the look of skin is a cosmetic. The same ingredient prescribed by a clinician and made by a pharmacy is a compounded drug, which brings in FDA's 503A rules.

How to read a copper-peptide label with FDA's intended-use test

FDA decides whether a product is a cosmetic or a drug by its intended use, and it looks at more than the label. Claims in advertising and online, what consumers expect the product to do, and ingredients with a well-known therapeutic use can all establish that intent ^[5].

FDA's own examples of drug claims include promises to restore hair growth or to regenerate cells ^[5]. Both are common on copper-peptide marketing. When you see them on a product sold as a cosmetic, you've learned something about the seller: it is either making a claim the law doesn't allow for a cosmetic, or it is selling a drug without following drug rules.

• Cosmetic wording: improves the look of fine lines, smoother-looking skin, a more even appearance.
• Drug wording: regenerates cells, rebuilds collagen, restores hair growth, heals wounds.
• What to do: read drug-style promises on a cosmetic as marketing, not as evidence, and ask a clinician if you want a treatment for a condition.

Small topical studies cannot establish general safety

The laser-resurfacing abstract does not give adverse-event rates ^[6]. Newer small reports still cannot exclude uncommon or long-term harm. In the scar add-on study, pigmentation occurred in 8 of 20 combination patients versus none with dermarolling alone ^[1]. That rate is specific to the procedure and products, not every cream.

For a compounded cream, the practical safety questions are the ones you'd ask of any pharmacy product: who made it, at what strength, and how it was tested. If a product causes irritation, stop using it and tell the prescriber or the brand.

Topical vs injected: why the route changes everything

The shared ingredient does not make topical and injected formulations interchangeable. Route, intended use, exposure and formulation matter. Compare the route-specific evidence and policy before interpreting a cream result as support for injection.

The BPC-157 guide illustrates the same need to distinguish investigational evidence, commercial compounding and drug approval. A study registration is not permission to market a product.

Terms used on this page

• Copper tripeptide-1: the cosmetic ingredient name for GHK-Cu.
• Cosmetic vs drug claim: a claim about appearance keeps a product a cosmetic; a claim about changing the body's structure or function makes it a drug.
• 503A Category 1: nominated ingredients FDA is still evaluating; it doesn't plan to act against licensed pharmacies compounding them under set conditions.
• Research use only: a label on chemicals sold for lab work, meaning the product isn't made or tested for people.
• Nominated but withdrawn: FDA's table for ingredients that left a category because their nominators withdrew; withdrawal does not establish approval or authorization.

Ongoing research is a plan, not a positive result

NCT07437586 currently lists a recruiting, paired-wound study with 60 estimated participants and no results. The sponsor’s protocol plans healing and safety outcomes; it does not establish a clinical benefit or a suitable commercial product ^[10].

Compare the exact topical offer before its headline price

A useful quote identifies the ingredient strength, amount dispensed, cosmetic or prescription status, selected term, complete charge, renewal schedule and dispensing pharmacy where relevant. Supply duration alone does not establish when you will be charged. Use the plan-inclusion checklist to organize a written quote.

The topical provider comparison links to reviews with product-specific pricing context. Its grades describe the published checks; they do not prove efficacy, verify every license or establish which pharmacy will fill your own order. Our method explains those limits.